Biotech startups that raised Series D or later in North America
Updated 16 Nov 2026
Not sure about the data?
Download a free 10-row sample first. No account, no payment.
| Company | City | Last round | Amount | Date |
|---|---|---|---|---|
| Opentrons | Long Island City | Series E | $40.0M | 2026-10-29 |
| Pathos | New York | Series E | $237.0M | 2026-10-23 |
| Circle Pharma | South San Francisco | Series E | $92.5M | 2026-09-16 |
| Alzheon | Framingham | Series F | $78.8M | 2026-09-10 |
| Socure | Incline Village | Series E | $156.0M | 2026-08-27 |
| Craif | Irvine | Series D | $24.4M | 2026-08-18 |
| Lycia Therapeutics | South San Francisco | Series D | $75.0M | 2026-06-25 |
| Element Biosciences | San Diego | Series E | $277.0M | 2026-06-09 |
8 rows of the CSV in 5 of its 18 columns.
- The 245 biotech startups in North America whose last round is Series D or later have raised $41.2B in total.
- 25 of them closed their most recent round in the last 12 months, $2.8B combined.
- The largest of those rounds is Enveda's $311.0M Series E, dated September 2026.
- The most recent is Opentrons' $40.0M Series E on 29 October 2026.
- Y Combinator is an investor in 4 of them, more than any other fund.
- Health care is the most common other sector, with 217 companies (89%).
- 1% were founded in 2020 or later; the median founding year is 2007.
- The most common team size is 11 to 50 employees (35% of companies with a recorded size).
- 8 are unicorns, valued at $1 billion or more.
Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.
Newest rounds
30 of 245| Company | What they do | Sector | Location | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|
| Opentrons Unicorn | Opentrons develops pipetting robots that automate laboratory experiments in the life sciences. | Artificial intelligence | Long Island City, United States | Series E | $40.0M | 2026-10-29 | $300.2M | Y Combinator, SOSV, Khosla Ventures +2 | 251 to 500 | 2014 |
| Pathos | Pathos is a biotechnology company that uses AI to speed up oncology drug development. | Artificial intelligence | New York, United States | Series E | $237.0M | 2026-10-23 | $684.0M | New Enterprise Associates, Lightbank, Builders VC +1 | 11 to 50 | 2022 |
| Circle Pharma | Circle Pharma develops bioavailable macrocyclic peptide therapeutics that target protein-protein interactions. | Biotech | South San Francisco, United States | Series E | $92.5M | 2026-09-16 | $300.0M | Mission BioCapital, Pfizer, The Column Group +1 | 11 to 50 | 2012 |
| Alzheon | Alzheon develops treatments for neurodegenerative disorders as a clinical-stage biotechnology company. | Biotech | Framingham, United States | Series F | $78.8M | 2026-09-10 | $343.3M | Ally Bridge Group, National Institute on Aging | 11 to 50 | 2013 |
| Socure Unicorn | Socure provides digital identity verification, fraud prevention, and regulatory compliance software. | Artificial intelligence | Incline Village, United States | Series E | $156.0M | 2026-08-27 | $900.4M | Accel, Citi Ventures, JP Morgan +1 | 501 to 1,000 | 2012 |
| Craif | Craif develops a cancer diagnosis algorithm using microRNA data and machine learning. | Artificial intelligence | Irvine, United States | Series D | $24.4M | 2026-08-18 | $68.7M | Global Brain Corporation, VentureOut, ANRI +1 | 51 to 100 | 2018 |
| Lycia Therapeutics | Lycia Therapeutics develops technology using lysosome-targeting chimeras to degrade disease-causing proteins. | Biotech | South San Francisco, United States | Series D | $75.0M | 2026-06-25 | $301.6M | Franklin Templeton, Alexandria Venture Investments, Invus +1 | 11 to 50 | 2019 |
| Element Biosciences Unicorn | Element Biosciences develops genomic sequencing and multiomics technologies for drug discovery and diagnostic applications. | Biotech | San Diego, United States | Series E | $277.0M | 2026-06-09 | $678.0M | RA Capital Management, Fidelity, Wellington Management +2 | 251 to 500 | 2017 |
| Click Therapeutics | Click Therapeutics develops and commercializes software-based prescription treatments for unmet healthcare needs. | Biotech | New York, United States | Series D | $50.0M | 2026-04-09 | $1.1B | Silicon Valley Bank, Accelmed, HSBC Innovation Banking +1 | 101 to 250 | 2012 |
| Numerion Labs | Numerion Labs develops artificial intelligence systems for drug discovery using deep learning algorithms. | Artificial intelligence | San Francisco, United States | Series D | $19.8M | 2026-03-19 | $241.4M | Y Combinator, Khosla Ventures, Creative Destruction Lab +1 | 11 to 50 | 2012 |
| Angitia Biopharmaceuticals | Angitia Biopharmaceuticals develops biologic therapies for musculoskeletal diseases. | Biotech | Westlake Village, United States | Series D | $130.0M | 2026-02-05 | $406.0M | Legend Capital, OrbiMed, Oriza Holdings +1 | 51 to 100 | 2018 |
| Elucid | Elucid applies AI to medical images to support precision medicine for cardiovascular disease. | Biotech | Boston, United States | Series D | $36.5M | 2025-10-22 | $166.2M | National Science Foundation, Sand Hill Angels, IAG Capital Partners +1 | 101 to 250 | 2013 |
| Avalyn Pharma | Avalyn Pharma develops therapies for idiopathic pulmonary fibrosis and other respiratory diseases. | Biotech | Seattle, United States | Series D | $100.0M | 2025-07-22 | $372.5M | Eight Roads Ventures, F-Prime, Wellington Management +2 | 11 to 50 | 2011 |
| Arthrosi Therapeutics | Arthrosi Therapeutics develops pharmaceutical treatments through clinical research and drug development programs. | Biotech | San Diego, United States | Series E | $153.0M | 2025-06-23 | $277.4M | Viva BioInnovator, Xiamen Changrong Investment Management, Viva Ventures Biotech Fund | 11 to 50 | 2018 |
| Variantyx | Variantyx offers molecular diagnostics and advanced genetic testing services. | Biotech | Framingham, United States | Series D | $36.0M | 2025-04-01 | $136.5M | Pitango VC, Bosch Ventures, Kreos Capital +2 | 101 to 250 | 2014 |
| Proscia | Proscia develops digital pathology software that helps laboratories manage and analyze pathology data. | Artificial intelligence | Philadelphia, United States | Series D | $50.0M | 2025-03-19 | $129.8M | Flybridge, Scale Venture Partners, Fusion Fund +2 | 101 to 250 | 2014 |
| Insilico Medicine | Insilico Medicine develops an AI platform for drug development targeting cancer and age-related diseases. | Artificial intelligence | Cambridge, United States | Series E | $123.0M | 2025-03-13 | $624.3M | Qiming Venture Partners, F-Prime, Warburg Pincus +1 | 101 to 250 | 2014 |
| GT Medical Technologies | GT Medical Technologies makes medical devices that offer new treatment options for brain tumor patients. | Biotech | Tempe, United States | Series D | $53.3M | 2025-01-16 | $162.5M | MedTech Innovator, Arizona Tech Investors, Gilde Healthcare +2 | 51 to 100 | 2017 |
| Clear Labs | Clear Labs is a biotechnology firm that uses a genomics system to simplify diagnostics. | Artificial intelligence | San Carlos, United States | Series D | $30.0M | 2025-01-13 | $156.5M | Plug and Play, Alumni Ventures, Khosla Ventures +1 | 51 to 100 | 2014 |
| Inari Unicorn | Inari is a seed design and biotechnology company developing seeds for a nature-positive food system. | Biotech | Cambridge, United States | Series G | $144.0M | 2025-01-07 | $753.0M | EDBI, Alexandria Venture Investments, CPP Investments +2 | 251 to 500 | 2016 |
| ONL Therapeutics | ONL Therapeutics develops biopharmaceuticals that protect photoreceptors to preserve vision. | Biotech | Ann Arbor, United States | Series D | $65.0M | 2024-09-13 | $147.9M | National Institutes of Health, Johnson & Johnson Innovation, Biosciences Research and Commercialization Center (BRCC) | 11 to 50 | 2011 |
| Moximed | Moximed develops therapies for patients with knee osteoarthritis. | Biotech | Hayward, United States | Series D | $61.0M | 2024-08-13 | $244.2M | New Enterprise Associates, Vertex Ventures, Cormorant Asset Management +1 | 11 to 50 | 2006 |
| Truvian Sciences | Truvian Sciences develops an automated benchtop system for lab-accurate blood testing. | Biotech | San Diego, United States | Series D | $74.0M | 2024-07-17 | $208.1M | General Catalyst, GreatPoint Ventures, Tao Capital Partners +2 | 101 to 250 | 2015 |
| TMRW Life Sciences | TMRW Life Sciences manages cryospecimens with automated, software-guided platforms. | Biotech | New York, United States | Series D | $28.2M | 2024-07-12 | $181.7M | Google Ventures, Casdin Capital, 5AM Ventures | 51 to 100 | 2018 |
| Formation Bio Unicorn | Formation Bio is a drug development company that aims to speed treatments to patients by reimagining clinical trials. | Artificial intelligence | New York, United States | Series D | $372.0M | 2024-06-26 | $528.0M | Andreessen Horowitz, Sequoia Capital, Thrive Capital +1 | 101 to 250 | 2013 |
| BillionToOne Unicorn | BillionToOne offers genetic testing that detects disease through precision diagnostics. | Biotech | Menlo Park, United States | Series D | $130.0M | 2024-06-21 | $425.9M | Y Combinator, 500 Global, UpHonest Capital +1 | 501 to 1,000 | 2016 |
| Nectero Medical | Nectero Medical develops a novel treatment to stabilize growth and prevent rupture of mid-sized abdominal aortic aneurysms. | Biotech | Tempe, United States | Series D | $96.0M | 2024-04-11 | $115.5M | Alumni Ventures, Norwest, Aphelion Capital +1 | 11 to 50 | 2017 |
| Emulate | Emulate creates advanced in vitro models to study how diseases, medicines, and chemicals affect human health. | Biotech | Boston, United States | Series F | $47.1M | 2024-03-20 | $271.3M | Alumni Ventures, Qiming Venture Partners, National Institutes of Health | 51 to 100 | 2013 |
| Perfect Day Unicorn | Perfect Day produces dairy proteins that are nutritionally identical to proteins from cow's milk. | Biotech | Berkeley, United States | Series E | $90.0M | 2024-01-05 | $801.5M | SOSV, K5 Global, Temasek +2 | 101 to 250 | 2014 |
| Lyndra Therapeutics | Lyndra Therapeutics creates oral dosage forms that release drugs over the long term. | Biotech | Watertown, United States | Series E | $101.0M | 2023-12-21 | $284.6M | Polaris Partners, Bill & Melinda Gates Foundation, Invus | 51 to 100 | 2015 |
Table 1. Biotech startups that raised Series D or later in North America: the 30 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 245.
Largest rounds
Last 12 months| # | Company | What they do | Sector | Location | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Element Biosciences Unicorn | Element Biosciences develops genomic sequencing and multiomics technologies for drug discovery and diagnostic applications. | Biotech | San Diego, United States | Series E | $277.0M | 2026-06-09 | $678.0M | RA Capital Management, Fidelity, Wellington Management +2 | 251 to 500 | 2017 |
| 2 | Pathos | Pathos is a biotechnology company that uses AI to speed up oncology drug development. | Artificial intelligence | New York, United States | Series E | $237.0M | 2026-10-23 | $684.0M | New Enterprise Associates, Lightbank, Builders VC +1 | 11 to 50 | 2022 |
| 3 | Socure Unicorn | Socure provides digital identity verification, fraud prevention, and regulatory compliance software. | Artificial intelligence | Incline Village, United States | Series E | $156.0M | 2026-08-27 | $900.4M | Accel, Citi Ventures, JP Morgan +1 | 501 to 1,000 | 2012 |
| 4 | Angitia Biopharmaceuticals | Angitia Biopharmaceuticals develops biologic therapies for musculoskeletal diseases. | Biotech | Westlake Village, United States | Series D | $130.0M | 2026-02-05 | $406.0M | Legend Capital, OrbiMed, Oriza Holdings +1 | 51 to 100 | 2018 |
| 5 | Circle Pharma | Circle Pharma develops bioavailable macrocyclic peptide therapeutics that target protein-protein interactions. | Biotech | South San Francisco, United States | Series E | $92.5M | 2026-09-16 | $300.0M | Mission BioCapital, Pfizer, The Column Group +1 | 11 to 50 | 2012 |
| 6 | Alzheon | Alzheon develops treatments for neurodegenerative disorders as a clinical-stage biotechnology company. | Biotech | Framingham, United States | Series F | $78.8M | 2026-09-10 | $343.3M | Ally Bridge Group, National Institute on Aging | 11 to 50 | 2013 |
| 7 | Lycia Therapeutics | Lycia Therapeutics develops technology using lysosome-targeting chimeras to degrade disease-causing proteins. | Biotech | South San Francisco, United States | Series D | $75.0M | 2026-06-25 | $301.6M | Franklin Templeton, Alexandria Venture Investments, Invus +1 | 11 to 50 | 2019 |
| 8 | Click Therapeutics | Click Therapeutics develops and commercializes software-based prescription treatments for unmet healthcare needs. | Biotech | New York, United States | Series D | $50.0M | 2026-04-09 | $1.1B | Silicon Valley Bank, Accelmed, HSBC Innovation Banking +1 | 101 to 250 | 2012 |
| 9 | Opentrons Unicorn | Opentrons develops pipetting robots that automate laboratory experiments in the life sciences. | Artificial intelligence | Long Island City, United States | Series E | $40.0M | 2026-10-29 | $300.2M | Y Combinator, SOSV, Khosla Ventures +2 | 251 to 500 | 2014 |
| 10 | Craif | Craif develops a cancer diagnosis algorithm using microRNA data and machine learning. | Artificial intelligence | Irvine, United States | Series D | $24.4M | 2026-08-18 | $68.7M | Global Brain Corporation, VentureOut, ANRI +1 | 51 to 100 | 2018 |
Table 2. Biotech startups that raised Series D or later in North America: the 10 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most active investors
By companies backed| # | Investor | Type | Location | Companies | Share | Funded, 12 months | Latest |
|---|---|---|---|---|---|---|---|
| 1 | Y Combinator | Startup accelerator | Mountain View, United States | 4 | 2% | 2 | Opentrons, Numerion Labs |
| 2 | RA Capital Management | Startup incubator | Boston, United States | 4 | 2% | 1 | Element Biosciences |
| 3 | Alumni Ventures | Angel group | Manchester, United States | 4 | 2% | ||
| 4 | National Institutes of Health | Entrepreneurship program | Bethesda, United States | 4 | 2% | ||
| 5 | Khosla Ventures | Venture capital firm | Menlo Park, United States | 3 | 1% | 2 | Opentrons, Numerion Labs |
| 6 | T. Rowe Price | Private equity firm | Baltimore, United States | 3 | 1% | 2 | Socure, Element Biosciences |
| 7 | Wellington Management | Private equity firm | Boston, United States | 3 | 1% | 1 | Element Biosciences |
| 8 | OrbiMed | Private equity firm | New York, United States | 3 | 1% | 1 | Angitia Biopharmaceuticals |
| 9 | Deerfield | Hedge fund | New York, United States | 3 | 1% | ||
| 10 | Google Ventures | Corporate venture arm | San Francisco, United States | 3 | 1% | ||
| 11 | Baillie Gifford | Private equity firm | Edinburgh, United Kingdom | 3 | 1% | ||
| 12 | Intel Capital | Corporate venture arm | Santa Clara, United States | 3 | 1% | ||
| 13 | SOSV | Venture capital firm | Princeton, United States | 2 | 1% | 1 | Opentrons |
| 14 | New Enterprise Associates | Venture capital firm | Menlo Park, United States | 2 | 1% | 1 | Pathos |
| 15 | MedTech Innovator | Startup accelerator | Los Angeles, United States | 2 | 1% | 1 | Craif |
Table 3. Biotech startups that raised Series D or later in North America: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Sectors
| Sectors | Companies | Share | Total raised |
|---|---|---|---|
| Health care | 217 | 89% | $34.3B |
| Software | 31 | 13% | $9.0B |
| Artificial intelligence | 19 | 8% | $7.2B |
| Hardware | 11 | 4% | $1.9B |
| Cybersecurity | 4 | 2% | $1.1B |
| Energy | 3 | 1% | $228.7M |
| Fintech | 2 | 1% | $973.0M |
| Commerce | 1 | 0% | $19.4M |
Table 4. Biotech startups that raised Series D or later in North America by sector. Source: FundingWatcher. Data as of 16 November 2026.
Funding stage
| Funding stage | Companies | Share | Median last round |
|---|---|---|---|
| Series D+ | 245 | 100% | $40.0M |
Table 5. Biotech startups that raised Series D or later in North America by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Countries
| Countries | Companies | Share |
|---|---|---|
| United States | 236 | 96% |
| Canada | 9 | 4% |
Table 6. Biotech startups that raised Series D or later in North America by headquarters country. Source: FundingWatcher. Data as of 16 November 2026.
Cities
| Cities | Companies | Share |
|---|---|---|
| San Diego | 18 | 7% |
| Cambridge | 12 | 5% |
| New York | 11 | 4% |
| South San Francisco | 11 | 4% |
| Redwood City | 9 | 4% |
| San Francisco | 7 | 3% |
| Boston | 5 | 2% |
| Santa Clara | 5 | 2% |
| Mountain View | 5 | 2% |
| Hayward | 4 | 2% |
| Berkeley | 4 | 2% |
| Durham | 4 | 2% |
Table 7. Biotech startups that raised Series D or later in North America by headquarters city. Source: FundingWatcher. Data as of 16 November 2026.
Rounds by month
| Rounds by month | Companies | Share | Raised |
|---|---|---|---|
| October 2026 | 3 | 12% | $327.7M |
| September 2026 | 4 | 16% | $757.3M |
| August 2026 | 5 | 20% | $434.4M |
| July 2026 | 1 | 4% | $67.4M |
| June 2026 | 2 | 8% | $352.0M |
| May 2026 | 2 | 8% | $92.0M |
| April 2026 | 3 | 12% | $170.0M |
| March 2026 | 1 | 4% | $19.8M |
| February 2026 | 2 | 8% | $245.0M |
| January 2026 | 2 | 8% | $305.0M |
Table 8. Biotech startups that raised Series D or later in North America: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most recent round by year
| Most recent round by year | Companies | Share | Raised |
|---|---|---|---|
| 2026 | 25 | 10% | $2.8B |
| 2025 | 22 | 9% | $2.1B |
| 2024 | 16 | 7% | $1.3B |
| 2023 | 12 | 5% | $1.1B |
| 2022 | 10 | 4% | $1.2B |
| 2021 | 21 | 9% | $1.5B |
Table 9. Biotech startups that raised Series D or later in North America by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Founding year
| Founding year | Companies | Share |
|---|---|---|
| 2020 to 2022 | 3 | 1% |
| 2015 to 2019 | 46 | 19% |
| 2010 to 2014 | 52 | 21% |
| Before 2010 | 142 | 58% |
Table 10. Biotech startups that raised Series D or later in North America by founding year. Source: FundingWatcher. Data as of 16 November 2026.
Team size
| Team size | Companies | Share |
|---|---|---|
| 1 to 10 | 19 | 8% |
| 11 to 50 | 84 | 35% |
| 51 to 100 | 69 | 28% |
| 101 to 250 | 34 | 14% |
| 251 to 500 | 17 | 7% |
| 501 to 1,000 | 12 | 5% |
| 1,001 to 5,000 | 4 | 2% |
| 5,001 to 10,000 | 2 | 1% |
| 10,001 or more | 2 | 1% |
Table 11. Biotech startups that raised Series D or later in North America by headcount. Source: FundingWatcher. Data as of 16 November 2026.
Method
- A company is on this list when Biotech is one of its sectors and its most recent funding round is Series D or later and its headquarters is in North America. On 16 November 2026 that is 245 companies.
- Stage, round, amount and date are those of the company's most recent funding round. Amounts are in US dollars as the source records them.
- The table prints the 30 newest rounds whose row is complete: a one-sentence description, a city, a named fund and an amount. The CSV carries all 245 rows: 18 have no round amount, 0 no city and 26 no website. The CSV carries domain, website, LinkedIn and the cached description sentence where present.
Sources, fields and exclusions of both files: Method.
Questions
- How many biotech startups in North America whose last round is Series D or later are on the list?
- 245, in the file dated 16 November 2026. 25 of them closed their most recent round in the last 12 months.
- What does the CSV contain?
- One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
- How much does the list cost?
- $29 one-time for all 245 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $199.
- What arrives after payment?
- At once: the CSV download link, on the page after payment and by mail.
- Can I see rows before buying?
- The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
- How current is the data?
- The file is dated 16 November 2026. The download link serves the current file each time it is opened.
Not sure about the data?
Download a free 10-row sample first. No account, no payment.